CHRONIC CONVECTION ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT HIGH GRADE GLIOMA
Study of Drug in Patients with Recurrent Brain Tumors (Glioma)
Sponsor: National Cancer Institute NCI
Enrolling: Male and Female Patients
IRB Number: AAAQ9520
U.S. Govt. ID: NCT03154996
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the safety of directly injecting a tumor chemotherapy drug called Topotecan and a contrast agent called Gadolinium into malignant brain tumors.
This study is closed
Investigator
Jeffrey Bruce, MD
Do You Qualify?
Have you been diagnosed with a recurrent malignant glioma? Yes No
Are you able to care for most of your personal needs with occasional assistance? Yes No
Are you willing to undergo a surgical operation? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE